ReWalk Robotics Names Jodi Gricci Chief Commercial Officer
Leading Exoskeleton Manufacturer Promotes Gricci, Expands Leadership Team
MARLBOROUGH, MA / YOKNEAM ILIT, ISRAEL, – ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”), leading manufacturer of exoskeleton systems, today announced the appointment of Jodi Gricci to the role of Chief Commercial Officer. Ms. Gricci previously served as Vice President, Global Marketing, Training, and Service while ReWalk established each of these functions to support customers. In addition, the company’s overall strategy with supporting the Veteran Affairs department; market development efforts for exoskeleton use for Spinal Cord Injured (SCI) individuals in the rehabilitation and home settings; and broad initiatives to gain support for individuals who need these type of technologies have been a major focus for Ms. Gricci.
“Jodi’s demonstrated commitment to the company and the larger community served by ReWalk has been an invaluable factor in the growth of this company. She has been a crucial part of many of the developments over the past 5 years, and we are excited to have her take on a larger executive role,” said Larry Jasinski, CEO of ReWalk Robotics.
In her new position, Ms. Gricci will lead expanded efforts on Capitol Hill in Washington; drive basic education and support for the rights of the disabled with many companies in the workplace; and provide continued leadership of the company’s customer facing departments. Ms. Gricci joined ReWalk in June 2012. Ms. Gricci established many of the key customer functions over the past 5 years; had significant involvement with ReWalk’s Initial Public Offering (IPO) in 2014; and the development of a first-ever national procurement policy established by the U.S. Department of Veteran Affairs in December 2015 which ensures all qualifying veterans with SCI access to their own ReWalk Robotics Personal system. Prior to ReWalk, Gricci served as the Managing Director of Soteira GmbH, a medical device company based in Berlin, Germany, from November 2008 to June 2012.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; the conclusion of ReWalk’s management, and the opinion of ReWalk’s auditors in their report on the Company’s consolidated financial statements for the fiscal year ended December 31, 2016, that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s ability to repay its secured indebtedness; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory actions with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to use effectively the proceeds of its 2016 follow-on offering; ReWalk’s ability to secure capital from its at-the-market equity distribution program based on the price range of its ordinary shares and conditions in the financial markets; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; ReWalk’s ability to regain compliance with NASDAQ continued listing requirements; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Lisa M. Wilson
In-Site Communications, Inc.
Datum: April 28, 2017